Cases & Deals

Aprea Therapeutics completes $97 million IPO

Clients Aprea Therapeutics, Inc.

Jones Day served as IP counsel in connection with the $97 million initial public offering of Aprea Therapeutics, Inc. (NASDAQ: APRE). Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.